The lack of frank tumor shrinkage and continued tumor growth, albeit at a slower rate, highlights the need for early noninvasive metabolic biomarkers of drug delivery, drug action, and response to mutant IDH inhibition using complementary noninvasive imaging methods such as 1H-MRS. Here, IDH2 is linked to neoplasm.